<DOC>
	<DOCNO>NCT00525577</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , dose-finding study design identify low AGI-1067 dose improve glycemic control measure HbA1c fast glucose subject Type 2 diabetes mellitus . Glycemic control measure 6-month treatment period subject 1 antidiabetic drug</brief_summary>
	<brief_title>ANDES-AGI-1067 Novel Antidiabetic Agent Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1 . Provide informed write consent prior entry . 2 . Be male female 1875 year age time entry Type 2 diabetes minimum 6 month prior Screening 1 visit . 3 . Have HbA1c level measure Screening 1 Screening 2 visit minimum level ≥7.5 % visit , determine core lab analysis . 4 . Be take either 1 antidiabetic agent . If antidiabetic medication , must sulphonylurea , metformin , glitazone class , dosage must stable last 3 month prior Screening 1 visit . Note combination medication ( i.e. , count 1 agent ) permit prior Randomization use GLP mimetrics , DPPIV inhibitor , colesevelam permit ( rescue medication allow 3 month ) . 5 . Subjects use hormone replacement therapy must stable dos hormone replacement therapy least 3 month prior Screening 1 visit . 6 . Females must breast feeding pregnant . If childbearing potential , must use reliable method birth control consider suitable Investigator . If hormonal contraceptive 6 month , subject allow participate study provide therapy remain constant throughout study period 2 month end study . 1 . Have Type 1 diabetes history ketoacidosis determine medical history 2 . Have HbA1c 10.5 % fast glucose &gt; 240 mg/dL ( 13.3 mmol/L ) either Screening 1 [ Visit 1 ] Screening 2 [ Visit 2 ] ) 3 . Have history severe diabetic neuropathy include autonomic neuropathy , gastroparesis , low limb ulceration amputation . 4 . Have history longterm therapy insulin ( &gt; 30 day ) within last year &gt; 7 day within last 3 month . 5 . Require parenteral corticosteroid recurrent continuous oral corticosteroid treatment ( &gt; 2 week ) within last 3 month . 6 . Use weight loss drug ( e.g. , orlistat , sibutramine , phenylpropanolamine , phentermine , similar prescription overthecounter medication ) within 3 month Screening 1 visit intentional weight loss ≥4 kg previous 6 month . 7 . Have new antidiabetic medication add , dose exist antidiabetic medication change , last 3 month prior Screening 1 visit . 8 . Have stroke , MI , coronary artery bypass graft ( CABG ) , percutaneous transluminal coronary angioplasty ( PTCA ) , admission unstable angina within last 6 month prior Screening 1 visit . 9 . Have congestive heart failure New York Heart Association Class III IV ( Appendix B ) . 10 . Have take follow drug 6 month prior Screening 1 visit : cholestyramine , colestid , cyclosporine , isotretinoin . 11 . Have acute infection require parenteral antibiotic treatment within last 3 month . 12 . Have uncontrolled hypertension ( define systolic blood pressure &gt; 180 mmHg ) . 13 . Have platelet &lt; 100,000 K/cu mm ( x 103/μL ) Screening 1 visit . 14 . Have active liver disease hepatic dysfunction ( total bilirubin , aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] &gt; 1.5 time upper limit normal [ ULN ] ) determine core lab analysis either Screening 1 visit Screening 2 visit . 15 . Subjects long QT syndrome evidence QTc Screening 1 visit &gt; 460 msec male &gt; 480 msec female subject take require continue therapy antiarrhythmic medication sotalol , quinidine , dofetilide , amiodarone drug know significantly prolong QT interval ( include drug associate minor effect QT interval le 15 msec . ) 16 . Have know major chronic infection major hematologic , renal , metabolic , gastrointestinal endocrine dysfunction judgment Investigator ( include diabetes mellitus severe allow subject safely participate study ) . 17 . Have lifethreatening illness history cancer malignancy within past 5 year ( except basal cell carcinoma ) . 18 . Have surgery require inpatient admission within 30 day prior Screening 1 visit . 19 . Considered unreliable study participant base Investigator 's ( designee 's ) knowledge subject ( e.g. , history alcohol drug abuse , inability unwillingness adhere protocol , psychosis ) . 20 . Have history intolerance previous use probucol within last 5 year . 21 . Have participate previous study AGI1067 . 22 . Have participate investigational drug study within 30 day prior study entry , expect participate investigational drug study course ANDES .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Type 2 diabetes , glycemic control</keyword>
</DOC>